Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The closing price of KalVista Pharmaceuticals Inc (NASDAQ: KALV) was $11.39 for the day, down -1.64% from the previous closing price of $11.58. In other words, the price has decreased by -$1.64 from its previous closing price. On the day, 1.1 million shares were traded. KALV stock price reached its highest trading level at $11.56 during the session, while it also had its lowest trading level at $10.93.
Ratios:
Our analysis of KALV’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 8.55 and its Current Ratio is at 8.55. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.03.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on June 15, 2020, initiated with a Buy rating and assigned the stock a target price of $30.
On July 29, 2019, SVB Leerink started tracking the stock assigning a Outperform rating and target price of $31.
On March 20, 2019, Needham started tracking the stock assigning a Buy rating and target price of $35.Needham initiated its Buy rating on March 20, 2019, with a $35 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Sep 09 ’24 when Palleiko Benjamin L sold 7,352 shares for $12.19 per share. The transaction valued at 89,622 led to the insider holds 250,800 shares of the business.
Audhya Paul K. sold 2,135 shares of KALV for $26,474 on Aug 23 ’24. The CHIEF MEDICAL OFFICER now owns 83,745 shares after completing the transaction at $12.40 per share. On Aug 23 ’24, another insider, Yea Christopher, who serves as the CHIEF DEVELOPMENT OFFICER of the company, sold 1,916 shares for $12.40 each. As a result, the insider received 23,758 and left with 85,676 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, KALV now has a Market Capitalization of 492224544 and an Enterprise Value of 324204224.
Stock Price History:
Over the past 52 weeks, KALV has reached a high of $16.88, while it has fallen to a 52-week low of $7.21. The 50-Day Moving Average of the stock is -8.37%, while the 200-Day Moving Average is calculated to be -8.45%.
Shares Statistics:
KALV traded an average of 365.65K shares per day over the past three months and 732130 shares per day over the past ten days. A total of 42.52M shares are outstanding, with a floating share count of 29.83M. Insiders hold about 30.97% of the company’s shares, while institutions hold 83.94% stake in the company. Shares short for KALV as of 1726185600 were 5719246 with a Short Ratio of 15.64, compared to 1723680000 on 5676914. Therefore, it implies a Short% of Shares Outstanding of 5719246 and a Short% of Float of 15.24.
